Fadi Braiteh, MD

Articles by Fadi Braiteh, MD

Evidence Supporting FTD/TPI ± Bevacizumab in mCRC

ByRyan Haumschild, PharmD, MS, MBA,Patrick Boland, MD,Fadi Braiteh, MD,Christine Parseghian, MD,Bassel El-Rayes, MD

October 15th 2025

Panelists discuss how the SUNLIGHT trial and real-world evidence support FTD/TPI with or without bevacizumab as an effective third-line option in metastatic colorectal cancer.

Overview of Available Third-Line Options in mCRC

ByRyan Haumschild, PharmD, MS, MBA,Patrick Boland, MD,Fadi Braiteh, MD,Christine Parseghian, MD,Bassel El-Rayes, MD

October 15th 2025

Panelists discuss how available third-line therapies, such as FTD/TPI, regorafenib, and others, are chosen based on survival data, safety, and patient quality of life.

Fadi Braiteh, MD

Articles by Fadi Braiteh, MD

Evidence Supporting FTD/TPI ± Bevacizumab in mCRC

Overview of Available Third-Line Options in mCRC

Latest Updated Articles

Trending on AJMC

Prescription Access Crisis: 40% of GLP-1 RA Rx Are Unfilled

FDA Expands Upadacitinib Label for Treating Inflammatory Bowel Disease

Experts, Patients Highlight Barriers to Arthritis Care Amid World Arthritis Day Observance

Efficacy and Safety of Dupilumab in AD Across Diverse Pediatric Populations: A Q&A With Elaine Siegfried, MD

Innovations and Challenges in Screening for Alzheimer Disease: Ken Cohen, MD, FACP